CNS Pharmaceuticals (CNSP) stock is skyrocketing after receiving a delisting notice from Nasdaq for failing to meet the minimum bid price requirement. Despite a temporary reprieve, the company faces an uphill battle to regain compliance, potentially leading to a delisting. This article explores the factors influencing the stock’s dramatic surge and the company’s uncertain future.